Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319566 · ClinicalTrials.gov registry record · Phase 3
Heart and Estrogen-Progestin Replacement Study (HERS)
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,430
- Enrollment target
NCT00319566 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 2,430 participants.
The verdict
NCT00319566, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,430 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.
Interventions
- DRUG Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,430 participants |
| Start Date | 1992-07 |
| Est. Completion | 2001-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319566
The ClinicalTrials.gov registry entry for NCT00319566 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily is the first listed.
NCT00319566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00319566 about?
NCT00319566 is a clinical study titled "Heart and Estrogen-Progestin Replacement Study (HERS)". The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.
What is the current status of trial NCT00319566?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,430 participants. The study started on 1992-07. Estimated completion is 2001-07.
What interventions are being tested in trial NCT00319566?
The interventions under investigation include: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily (DRUG).
Who is sponsoring clinical trial NCT00319566?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.